News

Drug pricing power led by hepatitis C, diabetes and cancer

Drug pricing power led by hepatitis C, diabetes and cancer

13-06-2014

Hepatitis C, diabetes and cancer are sustaining high pricing power through innovation according to Morningstar's…

AbbVieAntibiotics and Infectious diseasesBiogen IdecCopaxoneDiabetesGenericsGilead SciencesMerck & CoOncologyPharmaceuticalPricingTecfideraTeva Pharmaceutical IndustriesUSA

Case study draws attention to innovator brand preferences in Kenya

08-10-2013

Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

$200+ billion annual opportunity in USA from using medicines more responsibly, IMS finds

20-06-2013

Avoidable costs of more than $200 billion are incurred each year in the US health care system as a result…

Antibiotics and Infectious diseasesDiabetesFinancialGenericsHealthcareNorth AmericaPharmaceutical

US FDA pulls 27 Ranbaxy ANDAs approvals under consent decree

23-08-2012

The Food and Drug Administration is withdrawing approval of 27 Abbreviated New Drug Applications (ANDAs)…

Antibiotics and Infectious diseasesDaiichi SankyoDiabetesGenericsNorth AmericaRanbaxy LaboratoriesRegulation

Sanofi-Aventis in licensing deal with Vivalis for MAb targeting infectious diseases and extends accord with Zealand for diabetes product

08-06-2010

In what was another busy licensing day for French drug major Sanofi-Aventis, which since 2008 has already…

Antibiotics and Infectious diseasesDiabetesLantusLicensinglixisenatidePharmaceuticalSanofi PasteurSanofi-AventisVivalisZealand Pharma

US FDA approves Strativa’s Oravig, triggering a $20 million milestone for France’s BioAlliance; Agency could put hold on GSK

19-04-2010

US drugmaker Strativa Pharmaceuticals says that the Food and Drug Administration has approved Oravig…

Antibiotics and Infectious diseasesAvandiaBioAlliance PharmaDiabetesGlaxoSmithKlineNorth AmericaOravigPharmaceuticalRegulationStrativa

COMPANY SPOTLIGHT

Menarini

Back to top